Epitalon + MOTS-c Stack: Safety and Monitoring Guide

What human data exist for either peptide?

For Epitalon, FDA found three human studies: two sublingual studies in night-shift workers and one eye-injection study in retinitis pigmentosa. None assessed safety [1]. One small study gave no safety data, and a Russian-language abstract said only 'no side effects' without giving the dose, route, or number of participants [1]. FDA's adverse-event search through December 8, 2025 retrieved no Epitalon reports [1]. For MOTS-c, FDA found no published study giving it to a human and no animal toxicity studies. Its adverse-event search through March 9, 2025 retrieved no reports [2].

What safety questions remain open?

Neither peptide has human pharmacokinetic data, so no measured relationship exists between an injected amount and blood levels [1][2]. For injected peptides, FDA's stated concern is immunogenicity, an immune reaction to aggregates and peptide-related impurities [1][2][3]. For Epitalon, FDA described a mechanistic cancer concern. The peptide activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk. The mouse studies of cancer and chromosome damage used one fixed dose, female mice only and short exposure, which was too limited to show safety [1]. FDA also noted that MOTS-c breaks down quickly in human blood in vitro, which raises the question whether injecting it can produce active levels in people [2].

What do the FDA, HHS and WADA documents say?

Both peptides appear in the 'nominated but withdrawn' table on FDA's page about bulk substances that may present significant safety risks. Removal from category 2 was not a finding that either is safe [3]. Neither is on FDA's compounding lists for state-licensed pharmacies or for outsourcing facilities [8][9][10]. In July 2026 FDA staff proposed that neither be added to the pharmacy bulks list. The Pharmacy Compounding Advisory Committee voted in favor of both, against staff's recommendation, and those votes are non-binding advice [1][2][4][5].

HHS's draft enforcement-discretion policy (Federal Register document 2026-22192, filed October 28, 2026) names both peptides. It says HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with one of them if its conditions are met. It covers the acetate forms by subcutaneous or intramuscular injection [5][11]. Those conditions include a single active ingredient and a patient-specific prescription, so the draft does not extend to a product combining the two peptides [5][11]. The notice states it is not binding on HHS or the public [5].

WADA names MOTS-c in S4.4.1 as an AMPK activator, prohibited at all times in and out of competition, on both the 2026 and 2027 Lists [6][7]. Epitalon is not named on either list. The lists do not state whether it falls under the S0 category for substances with no regulatory approval for human therapeutic use [6][7].